Why this anti-aging drug startup thinks it's barking up the right tree

Biotech's efforts to extend life through drugs is going to the dogs. A San Francisco startup, backed by Laura Deming's anti-aging Longevity Fund, plans to take its first drug into clinical trials soon, using an existing drug to target a cellular mechanism believed to be responsible for large and giant breed dogs aging faster than smaller dogs. A second drug, aimed at "doggy dementia" and chronic kidney disease, also is expected to start a study in dogs this year. Cellular Longevity Inc. — or…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news